[go: up one dir, main page]

MX2017014872A - Metodos para preparar factor de von willebrand modificado. - Google Patents

Metodos para preparar factor de von willebrand modificado.

Info

Publication number
MX2017014872A
MX2017014872A MX2017014872A MX2017014872A MX2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A
Authority
MX
Mexico
Prior art keywords
methods
von willebrand
willebrand factor
preparing modified
modified von
Prior art date
Application number
MX2017014872A
Other languages
English (en)
Inventor
Schulte Stefan
Weimer Thomas
Wilhelm Beltz Hans-
Pestel Sabine
PELZING Matthias
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of MX2017014872A publication Critical patent/MX2017014872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención provee molóculas de Factor de von Willebrand modificadas, métodos para su preparación y usos de las mismas. La invención provee además composiciones farmacóuticas para el tratamiento de trastornos de coagulación.
MX2017014872A 2015-05-22 2016-05-20 Metodos para preparar factor de von willebrand modificado. MX2017014872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15168934 2015-05-22
PCT/EP2016/061440 WO2016188905A1 (en) 2015-05-22 2016-05-20 Methods for preparing modified von willebrand factor

Publications (1)

Publication Number Publication Date
MX2017014872A true MX2017014872A (es) 2018-07-06

Family

ID=53191564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014872A MX2017014872A (es) 2015-05-22 2016-05-20 Metodos para preparar factor de von willebrand modificado.

Country Status (16)

Country Link
US (3) US10772936B2 (es)
EP (2) EP4089109A3 (es)
JP (1) JP6651548B2 (es)
KR (1) KR20180012303A (es)
CN (1) CN107810194B (es)
AU (1) AU2016267539B2 (es)
BR (1) BR112017024714A2 (es)
CA (1) CA2986625A1 (es)
DK (1) DK3298036T3 (es)
ES (1) ES2912300T3 (es)
IL (1) IL255711A (es)
MX (1) MX2017014872A (es)
RU (1) RU2017145002A (es)
SG (2) SG11201708754XA (es)
TW (1) TW201713686A (es)
WO (1) WO2016188905A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908008T3 (es) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea
EP3538133B1 (en) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
KR20200018690A (ko) 2017-06-22 2020-02-19 체에스엘 베링 렝나우 아게 절단된 vwf에 의한 fviii 면역원성의 조절
AU2020300820A1 (en) * 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
WO2021067389A1 (en) * 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6399336B1 (en) * 1997-01-16 2002-06-04 Neose Technologies, Inc. Practical in vitro sialylation of recombinant glycoproteins
AU747391B2 (en) 1998-04-27 2002-05-16 Cantab Biopharmaceuticals Patents Limited Pharmaceutical composition comprising factor VIII and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002310438B2 (en) 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
AU2003227687B2 (en) 2002-04-29 2009-10-15 Stichting Sanquin Bloedvoorziening Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2572733A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
LT1824988T (lt) 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
JP2008537680A (ja) 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
EP3896090B1 (en) 2006-06-14 2022-01-12 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
SI2235197T1 (sl) 2007-12-27 2017-10-30 Baxalta GmbH Procesi celične kulture
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
SE537059C2 (sv) * 2012-12-21 2014-12-23 Nätstations Alliansen Ab Elcentral
EP3008084A2 (en) * 2013-06-12 2016-04-20 Novo Nordisk A/S Compounds suitable for treatment of haemophilia

Also Published As

Publication number Publication date
EP3298036B1 (en) 2022-04-06
BR112017024714A2 (pt) 2018-09-11
US20210121535A1 (en) 2021-04-29
US10772936B2 (en) 2020-09-15
US10905747B2 (en) 2021-02-02
EP4089109A2 (en) 2022-11-16
EP3298036A1 (en) 2018-03-28
RU2017145002A (ru) 2019-06-24
TW201713686A (en) 2017-04-16
AU2016267539A1 (en) 2017-11-16
CN107810194A (zh) 2018-03-16
IL255711A (en) 2018-04-30
US20180153968A1 (en) 2018-06-07
WO2016188905A1 (en) 2016-12-01
AU2016267539B2 (en) 2019-12-05
ES2912300T3 (es) 2022-05-25
HK1250724A1 (zh) 2019-01-11
SG11201708754XA (en) 2017-12-28
EP4089109A3 (en) 2023-03-01
JP2018515125A (ja) 2018-06-14
CA2986625A1 (en) 2016-12-01
SG10201910900WA (en) 2020-01-30
US11564976B2 (en) 2023-01-31
US20200368327A1 (en) 2020-11-26
KR20180012303A (ko) 2018-02-05
DK3298036T3 (da) 2022-06-07
JP6651548B2 (ja) 2020-02-19
CN107810194B (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP3350183C0 (en) SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE, COMPOSITIONS COMPRISING THEM AND METHODS OF USE THEREOF
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
WO2016077639A3 (en) Nanovesicular therapies
HK1251482A1 (zh) 用於治疗补体介导的疾病的组合物和方法
MX2017006692A (es) Trastornos neurodegenerativos.
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
TW201713686A (en) Methods for preparing modified von Willebrand factor
EP4480577A3 (en) Structured elements and methods of use
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
BR112017014229A2 (pt) conjugado, composição, e, método para tratamento de um distúrbio.
WO2014165563A3 (en) Uses of cyclic peptides for treating and preventing atherosclerosis

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CSL BEHRING LENGNAU AG